<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postnatal use of glucocorticoids for prevention of bronchopulmonary dysplasia (BPD) in preterm infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann R Stark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric C Eichenwald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinical trials have shown that postnatal systemic glucocorticoid therapy improves short-term lung function and pulmonary outcome of infants with established bronchopulmonary dysplasia (BPD) and reduces the risk of BPD in high-risk preterm infants. However, systemic glucocorticoid administration (primarily <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>) is associated with serious adverse effects (eg, increased risk of cerebral palsy [CP]). As a result, the potential benefits of routine administration of postnatal glucocorticoids appear to be outweighed by its downsides. Nevertheless, low-dose systemic glucocorticoid therapy may be beneficial in a select subset of patients (ie, those with evolving or established BPD who remain ventilator-dependent at two to four weeks after birth). (See  <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p>The use of postnatal glucocorticoid therapy in preterm infants to prevent BPD will be reviewed here. Antenatal glucocorticoid therapy, a broader discussion of strategies to prevent BPD, and management of established BPD are discussed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4992.html" rel="external">"Bronchopulmonary dysplasia (BPD): Prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H1661422376"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prematurity</strong> – Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birth weight (BW), as summarized in the table  (<a class="graphic graphic_table graphicRef119362" href="/z/d/graphic/119362.html" rel="external">table 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BPD</strong> – BPD is a chronic lung disease characterized disruption of pulmonary development and/or lung injury in the context of preterm birth. Clinically, BPD is defined as an ongoing need for supplemental oxygen and/or respiratory support at either 28 days postnatal age or 36 weeks postmenstrual age (PMA) in a preterm neonate with radiographic evidence of parenchymal lung disease  (<a class="graphic graphic_diagnosticimage graphicRef93656" href="/z/d/graphic/93656.html" rel="external">image 1</a>). Various criteria are used to define BPD, as summarized in the  (<a class="graphic graphic_table graphicRef119071" href="/z/d/graphic/119071.html" rel="external">table 2</a>) and discussed in detail separately. (see  <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Definitions and severity of BPD'</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopmental impairment (NDI)</strong> – NDI is a broad term that generally includes cognitive, motor, sensory, behavioral, and/or psychologic impairments. Severe NDI is commonly defined in research studies as the presence of <strong>any</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive delay (ie, ≥2 standard deviations (SD) below the mean on standardized assessments)</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe cerebral palsy (CP) </p><p class="bulletIndent2"><span class="glyph">•</span>Severe bilateral hearing loss </p><p class="bulletIndent2"><span class="glyph">•</span>Severe visual impairment </p><p></p><p class="bulletIndent1">NDI in preterm infants is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">SYSTEMIC GLUCOCORTICOIDS</span></p><p class="headingAnchor" id="H3371327576"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>Because inflammation is thought to play a key role in the pathogenesis of BPD, the use of glucocorticoids to suppress inflammation has been of an area of active clinical research [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Pathogenesis'</a>.) </p><p>In addition, relative adrenal insufficiency has been described in extremely preterm (EPT) infants (gestational age [GA] &lt;28 weeks) due to impaired synthesis or release of adrenocortical hormones and this may contribute to hemodynamic and respiratory instability in the early postnatal course [<a href="#rid2">2</a>]. It has been suggested that administration of low-dose glucocorticoid therapy as a replacement for this relative deficiency may have a beneficial effect. (See  <a class="medical medical_review" href="/z/d/html/126605.html" rel="external">"Neonatal shock: Management", section on 'Suspected adrenal insufficiency'</a>.)</p><p class="headingAnchor" id="H1096206111"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Our approach in the use of postnatal systemic glucocorticoid therapy to prevent BPD is based on review of the available literature and is consistent with the recommendations of restrictive use of systemic glucocorticoid therapy to prevent BPD in the preterm infant by both the American Academy of Pediatrics and the Canadian Paediatric Society (AAP/CPS) [<a href="#rid3">3,4</a>] (see <a class="local">'General efficacy'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>We recommend <strong>against</strong> the routine use of postnatal systemic glucocorticoids to prevent BPD for all EPT infants at risk for BPD. Although prophylactic systemic glucocorticoids reduce the risk of BPD, this approach would unnecessarily expose the majority of EPT infants, who would not develop BPD, to the known short-term and long-term adverse effects of glucocorticoids. (See <a class="local">'General efficacy'</a> below and <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest using systemic glucocorticoids selectively in EPT infants who remain ventilator-dependent at a postnatal age of two to four weeks and in whom attempts to wean from the ventilator have failed and/or who require oxygen supplementation &gt;50 percent [<a href="#rid5">5-7</a>]. These infants are at high risk for developing BPD.</p><p></p><p class="bulletIndent1">In this setting, we administer low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> according to the protocol used in DART (Dexamethasone: A Randomized Trial) (see <a class="local">'Dosing'</a> below). Parents/caregivers should be informed of the risks and benefits and should participate in decision-making. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also reserve the use of systemic glucocorticoid for "rescue therapy" in select older infants (≥36 weeks postmenstrual age [PMA]) with established BPD who require sustained ventilatory and oxygen support or are experiencing an episode of acute pulmonary deterioration. Such infants should first be evaluated for other causes of lung disease, including ventilator-associated pneumonia, progressive pulmonary hypertension, or the development of bronchomalacia. Use of glucocorticoids in this setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Glucocorticoids'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">General efficacy</span><span class="headingEndMark"> — </span>The efficacy of postnatal systemic glucocorticoid therapy, either routinely administered during the first week after birth or used selectively in older infants with ongoing mechanical ventilator-dependence, for preventing development of BPD is supported by clinical trials and meta-analyses [<a href="#rid8">8-12</a>]. In general, the available evidence suggests that the benefits of routine postnatal systemic glucocorticoid therapy are outweighed by the adverse effects. (See <a class="local">'Adverse effects'</a> below.). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early use (within first 7 to 10 days)</strong> – In a meta-analysis of 26 trials (4167 neonates), early glucocorticoid therapy administered within the first 7 to 10 days after birth decreased the incidence of BPD at 36 weeks PMA compared with placebo (25 versus 31 percent; relative risk [RR] 0.80, 95% CI 0.73-0.88) [<a href="#rid9">9</a>]. Mortality was similar in both groups. As discussed below, the beneficial effect in reducing rates of BPD was seen only in trials of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>, whereas trials involving <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> did not detect a significant reduction in BPD. (See <a class="local">'Dexamethasone'</a> below and <a class="local">'Hydrocortisone'</a> below.)</p><p></p><p class="bulletIndent1">However, early glucocorticoid therapy, particularly with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>, is associated with increased risk of cerebral palsy (CP) in long-term follow-up. Glucocorticoid therapy is also associated with an increased risk of gastrointestinal perforation, as discussed below. (See <a class="local">'Adverse effects'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later use in infants with evolving or established BPD</strong> – In a meta-analysis of 21 trials involving 1428 infants &gt;7 days old with ongoing ventilator dependence, late administration of glucocorticoid therapy reduced mortality compared with control (18 versus 23 percent; RR 0.81, 95% CI 0.66-0.99), and reduced the incidence of BPD at 36 weeks PMA (53 versus 59 percent, RR 0.89, 95% CI 0.80-0.99; 14 trials, 988 neonates) [<a href="#rid11">11</a>]. In subgroup analyses, a significant reduction in BPD was detected in trials using <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> but not in trials using <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a>. (See <a class="local">'Dexamethasone'</a> below and <a class="local">'Hydrocortisone'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Adverse effects</span></p><p class="headingAnchor" id="H1420214904"><span class="h3">Short-term</span><span class="headingEndMark"> — </span>In the previously mentioned meta-analyses, postnatal systemic glucocorticoids were associated with the following short-term adverse effects [<a href="#rid9">9,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal perforation </p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy</p><p></p><p>Two trials were stopped early because of increased rates of intestinal perforation in the active treatment groups compared with placebo; one of these trials involved <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> [<a href="#rid13">13</a>], the other <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> [<a href="#rid14">14</a>]. In a meta-analysis of 16 trials, early glucocorticoid treatment was associated with a higher incidence of intestinal perforation compared with placebo (7 versus 4 percent; RR 1.84, 95% CI 1.36-2.49) [<a href="#rid9">9</a>]. The risk was similar regardless of agent (dexamethasone or hydrocortisone). A separate meta-analysis examining late glucocorticoid treatment was inconclusive as to the risk of intestinal perforation as there were few events (16 total events out of 552 neonates) [<a href="#rid11">11</a>]. The risk of intestinal perforation is heightened when glucocorticoids are administered concomitantly with <a class="drug drug_pediatric" data-topicid="13380" href="/z/d/drug information/13380.html" rel="external">indomethacin</a>.</p><p class="headingAnchor" id="H6"><span class="h3">Long-term</span><span class="headingEndMark"> — </span>Follow-up studies have raised concerns that postnatal systemic glucocorticoid therapy contributes to neurodevelopmental impairment (NDI), especially CP [<a href="#rid15">15-18</a>]. In a meta-analysis of trials involving early administration of glucocorticoids (within first seven days after birth), long-term data showed early glucocorticoid treatment was associated with increased risk CP compared with control (11 versus 7 percent; RR 1.42, 95% CI 1.06-1.91) [<a href="#rid9">9</a>]. However, as discussed below, the increased risk of CP was seen only in trials involving <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>, not in trials involving <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a>. (See <a class="local">'Dexamethasone'</a> below and <a class="local">'Hydrocortisone'</a> below.)</p><p class="headingAnchor" id="H3399161560"><span class="h2">Specific agents</span></p><p class="headingAnchor" id="H3188233082"><span class="h3">Dexamethasone</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> is the glucocorticoid agent most commonly used in the prevention and treatment of BPD. Randomized clinical trials have shown that it reduces the risk of BPD [<a href="#rid9">9-11,19</a>]. However, postnatal dexamethasone therapy is associated with serious adverse effects, including CP, especially when high doses are used within the first week after birth [<a href="#rid9">9,10,19</a>]. As a result, we continue to recommend <strong>against</strong> routine early dexamethasone therapy [<a href="#rid20">20</a>]. However, the benefit-risk ratio depends on the underlying risk of BPD [<a href="#rid16">16,21</a>]. In high-risk patients (ie, older infants with evolving or established BPD who remain ventilator-dependent after two to four weeks), the benefits of low-dose dexamethasone likely outweigh the risk of adverse effects [<a href="#rid11">11,22</a>]. (See <a class="local">'Our approach'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early use (within first 7 to 10 days)</strong> – Randomized trials and meta-analyses evaluating <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> given early (within the first 7 to 10 days after birth) have reported the following findings [<a href="#rid9">9,10,14,19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No apparent effect on mortality – In a meta-analysis of 20 trials (n=2940 neonates), mortality rates were similar in infants randomized to early <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> treatment compared with control (24 percent each; RR 1.02, 95% CI 0.90-1.16) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower incidence of BPD at 36 weeks PMA – A meta-analysis of 17 trials (n=2791 neonates) early <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> therapy reduced rates of BPD at 36 weeks PMA compared with control (19 versus 27 percent; RR 0.72, 95% CI 0.63-0.82) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased incidence of NDI – In a meta-analysis of seven trials (n=921 neonates), rates of CP were higher among infants who received early <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> treatment compared with control (16 versus 9 percent; RR 1.77, 95% CI 1.21-2.58) [<a href="#rid9">9</a>]. Rates of major neurosensory disability (ie, hearing or vision impairment) were also higher in the dexamethasone group (22 versus 16 percent; RR 1.37, 95% CI 1.03-1.83). Other neurodevelopmental outcomes (eg, standardized cognitive and motor assessments) were not consistently reported in the different trials. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later use</strong> <strong>(after first 7 to 10 days)</strong> – Randomized trials and meta-analyses evaluating use of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> in neonates who remain ventilator-dependent beyond the first 7 to 10 days after birth have reported the following findings [<a href="#rid8">8,10,11,17,23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uncertain effect on mortality – A meta-analysis of 19 randomized trials (n=993 neonates) did not detect a difference in mortality between infants treated with late <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> compared with control (16 versus 19 percent; RR 0.85, 95% CI 0.66-1.11) [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced incidence of BPD at 36 weeks PMA – In a meta-analysis of 12 randomized trials (n=553 neonates), late <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> therapy reduced the incidence of BPD at 36 weeks PMA compared with control (50 versus 66 percent; RR 0.76, 95% CI 0.66-0.87) [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Earlier extubation – In a meta-analysis of 16 randomized trials (n=783 neonates), infants treated with late <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> were less likely to remain intubated after seven days of treatment (55 versus 83 percent; RR 0.66, 95% CI 0.6-0.73) [<a href="#rid11">11</a>]. Similar findings were reported in an observational study in which approximately 80 percent of treated infants were successfully extubated within 14 days of starting dexamethasone [<a href="#rid24">24</a>].  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uncertain effect on NDI – A meta-analysis of 17 randomized trials (n=1290 neonates), did not detect a significant difference in rates of CP in later childhood among neonates treated with late <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> compared with control (14 versus 12 percent; RR 1.12, 95% CI 0.79-1.60) [<a href="#rid11">11</a>]. </p><p></p><p class="headingAnchor" id="H4226848623"><span class="h3">Hydrocortisone</span><span class="headingEndMark"> — </span>When a decision is made to treat with glucocorticoids, we generally prefer low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> over <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a>. Clinical trials directly comparing the two agents are lacking. Although the available trials evaluating hydrocortisone in this setting suggest that the risk of NDI may be lower with this agent, its efficacy for reducing BPD among neonates with ongoing ventilator dependence is less certain. Some of the uncertainty in this area stems from the considerable variability between trials regarding the timing and dosing of hydrocortisone. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early use (within first 7 to 10 days)</strong> – Randomized trials and meta-analyses evaluating <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> given early (within the first 7 to 10 days after birth) at a low dose (1 to 2 mg/kg per day) have reported the following findings [<a href="#rid9">9,25-30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced mortality – In a meta-analysis of 11 randomized trials (n=1433 neonates) early treatment with <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> reduced in-hospital mortality compared with control (18 versus 22 percent; RR 0.80, 95% CI 0.65-0.99) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No apparent effect on rates of BPD at 36 weeks PMA – A meta-analysis of nine randomized trials (n=1376 neonates) did not detect a significant difference in rates of BPD at 36 weeks PMA among neonates treated with early <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> compared with control (35 versus 38 percent; RR 0.92, 95% CI 0.81-1.06) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No apparent effect on rates of NDI – In a meta-analysis of six randomized trials (n=1052 neonates), rates of cerebral palsy (CP) in later childhood were similar in both groups (6 percent each; RR 1.05, 95% CI 0.66-1.66), as were rates of neurosensory disability (ie, hearing or vision impairment) (15 versus 17 percent; RR 0.86, 95% CI 0.64-1.14) [<a href="#rid9">9</a>]. Other neurodevelopmental outcomes (eg, standardized cognitive and motor assessments) were not consistently reported in the different trials. In the largest trial, which included 523 EPT infants, neurodevelopmental outcomes at a median corrected age of 22 months were similar in both groups (rates of moderate to severe NDI were 7 versus 11 percent; rates of mild NDI were 20 versus 18 percent) [<a href="#rid30">30</a>]. In a subgroup analysis limited to infants born at 24 to 25 weeks GA, the rate of NDI was lower in infants randomized to <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> compared with placebo, but the exploratory nature of this subgroup analysis and the small number of events preclude drawing firm conclusions [<a href="#rid31">31</a>]. Magnetic resonance imaging (MRI) at term equivalent age performed in 300 of the 412 survivors demonstrated a higher score for white matter abnormality for the hydrocortisone versus control groups [<a href="#rid32">32</a>]. However, after adjusting for GA and other risk factors, MRI scores were similar between the two groups. Observational studies have also generally reported similar neurodevelopmental outcomes in preterm infants treated with or without hydrocortisone [<a href="#rid33">33-36</a>]; although some studies have reported worse neurodevelopmental outcomes among hydrocortisone-treated infants [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later use</strong> <strong>(after first 7 to 10 days)</strong> – Randomized trials and meta-analyses evaluating use of <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> at higher doses (3 to 5 mg/kg per day) in neonates who remain ventilator-dependent beyond the first 7 to 10 days after birth have reported the following findings [<a href="#rid11">11,37-40</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uncertain effect on mortality – In a meta-analysis of two randomized trials (n=435 neonates) mortality was lower among neonates treated with late <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> compared with control; however the finding was not statistically significant (23 versus 30 percent; RR 0.74, 95% CI 0.54-1.02) [<a href="#rid11">11</a>]. In a subsequent randomized trial published after the meta-analysis, in-hospital mortality was similar in neonates who received late hydrocortisone treatment (at 14 to 28 days) compared with placebo (9 versus 10 percent; RR 0.86, 95% CI 0.56-1.31) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No apparent effect on rates of BPD at 36 weeks PMA – In a meta-analysis of two randomized trials (n=435 neonates), rates of BPD at 36 weeks PMA were similar in both groups (57 versus 52 percent; RR 1.10, 95% CI 0.92-1.31) [<a href="#rid11">11</a>]. Similar findings were reported in a subsequent randomized trial published after the meta-analysis, in which rates of BPD at 36 weeks PMA were comparable in both groups (83 versus 86 percent; RR 0.96, 95% CI 0.91-1.02) [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Earlier extubation – In the two trials that reported extubation rates, infants treated with late <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> were more likely to be extubated within one to two weeks after starting treatment [<a href="#rid37">37,38</a>]. For example, in a multicenter trial involving 800 infants &lt;30 weeks GA who were ventilator-dependent at 14 to 28 days postnatal age, more infants in the hydrocortisone group were successfully extubated during the 10-day treatment period compared with placebo (45 versus 34 percent; RR 1.54, 95% CI 1.23-1.93) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No apparent effect on rates of NDI – A meta-analysis of two randomized trials (n=435 neonates), did not detect a significant difference in rates of CP in later childhood among neonates treated with late <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> compared with control (28 versus 34 percent; RR 0.82, 95% CI 0.62-1.08) [<a href="#rid11">11</a>]. Similarly, in a subsequent randomized trial published after the meta-analysis, rates of moderate to severe NDI among survivors were comparable in both groups (58 versus 57 percent; RR 1.03, 95% CI 0.90-1.17) [<a href="#rid38">38</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The risk of adverse effects of glucocorticoid therapy appears to increase with increasing cumulative dose [<a href="#rid20">20,41,42</a>]. An optimal dose that provides maximal benefit while minimizing adverse effects has not been established. Decisions regarding criteria for starting postnatal glucocorticoid therapy, preferred agent, and dosing remain center dependent. In our centers, we selectively use low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> only in patients who are at high risk of developing BPD (ie, ventilator- or oxygen-dependent after two to four weeks postnatal age). (See <a class="local">'Our approach'</a> above.)</p><p>We administer low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> according to the protocol used in DART (Dexamethasone: A Randomized Trial), which provides intravenous dexamethasone (cumulative dose 0.89 mg/kg) as follows [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>0.075 mg/kg per dose 12 hourly for three days, then,</p><p class="bulletIndent1"><span class="glyph">●</span>0.05 mg/kg per dose 12 hourly for three days, then,</p><p class="bulletIndent1"><span class="glyph">●</span>0.025 mg/kg per dose 12 hourly for two days, then,</p><p class="bulletIndent1"><span class="glyph">●</span>0.01 mg/kg per dose 12 hourly for two days, then discontinue</p><p></p><p>Several cohort studies have reported an increasing risk of neurologic impairment with higher doses of glucocorticoid therapy or longer duration of therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter prospective cohort study reported that for infants exposed to postnatal glucocorticoid therapy (<a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> in 92 percent of cases) an increase of 1 mg/kg in dexamethasone dose was associated with a two-point reduction in the Bayley mental development index (MDI) score, and a 40 percent increase in risk for disabling CP at 18 to 22 months corrected age [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the EPICure study (a large English prospective cohort study of preterm infants born &lt;26 weeks gestation), increasing duration of postnatal steroid treatment was associated with poor motor outcomes. [<a href="#rid42">42</a>].</p><p></p><p>In a network meta-analysis that included 14 trials that used different glucocorticoid regimens (ie, different agents [<a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> or <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a>], timing of administration [early versus late], and/or cumulative daily dose [low, moderate, or high]), dexamethasone given between 8 to 14 days after birth at moderate dose was the regimen associated with lowest risk of BPD or morality at a PMA of 36 weeks compared with the other 13 regimens [<a href="#rid43">43</a>]. However, the indirect nature of these comparisons limit the certainty of this finding.</p><p class="headingAnchor" id="H339202288"><span class="h2">Trends in practice over time</span><span class="headingEndMark"> — </span>The use of postnatal systemic glucocorticoid therapy in preterm neonates has declined considerably since the late 1990s and early 2000s when concerns first surfaced about long-term adverse effects. There was further decline after 2010 when the AAP published guidelines recommending against postnatal glucocorticoid therapy due to these concerns. </p><p>Several population-based studies examining the impact of diminished glucocorticoid use on the incidence and severity of BPD have reported conflicting results. A study of three large neonatal network databases in North America reported that a reduction in steroid use starting in 1999 was <strong>not</strong> associated with significant changes in mortality or the incidence and severity of BPD [<a href="#rid44">44</a>]. In contrast, several studies have reported an increase in the incidence of BPD with varying effects on mortality. One retrospective study of extremely low birth weight (ELBW) infants (BW &lt;1000 g) reported that decreased use of postnatal glucocorticoid therapy was associated with an increase in the incidence of BPD without a change in mortality [<a href="#rid45">45</a>]. There was also no change in the rate of major NDI. In another population-based study found a reduction in postnatal glucocorticoid use was associated with a decrease in mortality and an increased incidence of BPD for preterm infants (GA 24 to 32 weeks) [<a href="#rid46">46</a>]. These findings support the notion that prophylactic glucocorticoids are effective in reducing the incidence of BPD. (See <a class="local">'General efficacy'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h2">Unanswered questions</span><span class="headingEndMark"> — </span>As discussed in the previous sections, we recommend against routine use of postnatal glucocorticoid therapy since the available evidence suggests that the potential benefits do not outweigh the known complications of this intervention [<a href="#rid3">3,4</a>]. However, it remains uncertain whether there is a clinical setting in which postnatal glucocorticoid therapy would be beneficial despite the risk of adverse effects.</p><p>Well-powered randomized controlled trials with adequate follow-up are still needed to answer the following questions [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Can we identify a subpopulation of preterm infants for whom the benefits of postnatal glucocorticoids clearly outweigh the risks? </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If glucocorticoid therapy is used, what is the optimal regimen (ie, agent, timing, dosing)? (See <a class="local">'Specific agents'</a> above and <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do short-term improvements in pulmonary function associated with glucocorticoid administration convey additional long-term pulmonary benefits (eg, prevention of long-term severe pulmonary complications of BPD, including severe pulmonary hypertension and cor pulmonale)? (See  <a class="medical medical_review" href="/z/d/html/6379.html" rel="external">"Complications and long-term pulmonary outcomes of bronchopulmonary dysplasia"</a>.)</p><p></p><p class="headingAnchor" id="H3699413622"><span class="h1">OTHER ROUTES OF ADMINISTRATION</span></p><p class="headingAnchor" id="H12"><span class="h2">Inhaled glucocorticoids</span><span class="headingEndMark"> — </span>It has been proposed that inhaled glucocorticoids might be an effective and safer alternative for preventing BPD in at-risk EPT infants rather than using systemic glucocorticoids, since the latter is associated with long-term neurodevelopmental impairment (NDI), as discussed above (see <a class="local">'Adverse effects'</a> above). However, postnatal administration of inhaled glucocorticoids has not consistently been shown to reduce the risk of BPD, and there are concerns about a possible increased mortality risk. </p><p class="headingAnchor" id="H2141455549"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Routine use for prevention of BPD – Based upon available data (described below), we suggest <strong>not</strong> routinely using inhaled glucocorticoids to prevent BPD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of severe BPD – Despite the limited data on the efficacy of inhaled glucocorticoids, we do selectively use inhaled glucocorticoids in older infants if they have severe BPD, are dependent upon substantial ventilator and oxygen support, and have signs of severe airway obstruction or reactive airway disease. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Glucocorticoids'</a>.)</p><p></p><p class="headingAnchor" id="H2018123065"><span class="h3">Evidence</span><span class="headingEndMark"> — </span>Based on the available clinical trial data, postnatal administration of inhaled glucocorticoids does not appear to meaningfully reduce the risk of BPD, and some studies suggest a possible increased mortality risk [<a href="#rid48">48-50</a>]. </p><p>In a meta-analysis of six trials involving mechanically ventilated preterm neonates randomized to <strong>early</strong> (in the first two weeks after birth) inhaled glucocorticoid therapy or placebo, rates of BPD at 28 days of age or 36 weeks postmenstrual age (PMA) were similar in both groups (15 percent in each; relative risk [RR] 0.97, 95% CI 0.62-1.52) [<a href="#rid48">48</a>]. Mortality was also similar at 36 weeks PMA (14 and 15 percent, respectively). However, inhaled glucocorticoids reduced the incidence of BPD among survivors (24 versus 31 percent; RR 0.76, 95% CI 0.63-0.93). Adverse events were similar between the two groups.</p><p>The largest trial in the above meta-analysis was the NEUROSIS trial (Neonatal EUROpean Study of Inhaled Steroids). A follow-up study of the NEUROSIS trial reported that of the 813 infants for whom vital status was known at two years, there were more deaths in the inhaled glucocorticoid group compared with placebo (20 versus 15 percent; RR 1.37 95% CI 1.01-1.86) [<a href="#rid49">49</a>]. Rates of NDI among survivors were similar in both groups (48 versus 51 percent; adjusted RR 0.93, 95% CI 0.80-1.09).</p><p>There are fewer data on use of <strong>late</strong> (&gt;7 days after birth) inhaled glucocorticoid therapy in preterm neonates with ongoing need for mechanical ventilation or oxygen beyond the first week after birth. In a meta-analysis five placebo-controlled trials (n=79), infants who received late inhaled glucocorticoid therapy were less likely to remain intubated after seven days of treatment (74 versus 95 percent; RR 0.80, 95% CI 0.66-0.98) [<a href="#rid50">50</a>]. However, overall duration of mechanical ventilation was similar in both groups. No firm conclusions could be reached regarding the effect of inhaled glucocorticoids on mortality, rates of BPD at 36 weeks PMA, or serious adverse events because these outcomes were inconsistently reported and/or there were few events. Another important limitation of these data is the considerable heterogeneity between trials. In addition, most of the trials were performed in the late 1990s to early 2000s and the applicability to modern-day practice is unclear.</p><p class="headingAnchor" id="H3082079009"><span class="h2">Intratracheal glucocorticoids</span><span class="headingEndMark"> — </span>Because of the concerns for adverse effects associated with systemic steroids (eg, increased risk of cerebral palsy), postnatal intratracheal delivery of glucocorticoids mixed with surfactant was proposed as an alternative. However, we suggest <strong>not</strong> using this approach as it remains uncertain whether intratracheal glucocorticoid therapy is effective and safe in extremely preterm (EPT) neonates at risk for BPD. </p><p>Two randomized controlled trials from a single center examined early administration of intratracheal <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> at 0.25 mg/kg mixed in surfactant compared with surfactant alone in infants &lt;1500 g [<a href="#rid51">51-55</a>]. In a meta-analysis that pooled the results of both trials plus three other smaller trials (n=549 infants), rates of BPD were lower in the budesonide group compared with control (22 versus 42 percent; RR 0.58, 95% CI 0.41-0.82) [<a href="#rid54">54</a>]. Short-term mortality was also lower in the budesonide group (13 versus 20 percent; RR 0.64, 95% CI 0.41-0.99). A separate meta-analysis assessing long-term outcomes at age 18 to 36 months did not detect a difference in rates of neurodevelopmental impairment (31 versus 39 percent; RR 0.78, 95% CI 0.55-1.11) or long-term mortality (18 versus 24 percent; RR 0.76, 95% CI 0.52-1.11). [<a href="#rid56">56</a>].</p><p>The results of these trials need to be replicated in larger multicenter trials before use of intratracheal <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> can be recommended as a routine.</p><p class="headingAnchor" id="H3089099186"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115866.html" rel="external">"Society guideline links: Bronchopulmonary dysplasia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for postnatal glucocorticoid therapy</strong> ‒ Because inflammation is thought to play a key role in the pathogenesis of bronchopulmonary dysplasia (BPD), the use of glucocorticoids to suppress inflammation has been proposed to prevent BPD in high-risk preterm infants, particularly extremely preterm (EPT) infants (&lt;28 weeks gestation). (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoid therapy</strong> ‒ The potential benefits of postnatal glucocorticoid therapy must be weighed against the adverse effects, which include hyperglycemia, hypertension, gastrointestinal perforation, and risk of neurodevelopmental impairment (eg, cerebral palsy [CP]). The optimal approach to identifying patients who are likely to benefit from postnatal glucocorticoid therapy, selecting a glucocorticoid agent, timing of treatment, and dosing remain uncertain. Practice varies between centers. Our general approach is as follows (see <a class="local">'Systemic glucocorticoids'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For EPT infants who do not require mechanical ventilation, we recommend <strong>against</strong> routine use of systemic glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Although postnatal systemic glucocorticoid therapy reduces the risk of BPD, it is associated with serious adverse effects, particularly increased risk of CP. Thus, the potential benefits of routine postnatal glucocorticoid therapy in this population appear to be outweighed by its downsides. (See <a class="local">'Our approach'</a> above and <a class="local">'General efficacy'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For EPT infants who remain ventilator- and oxygen-dependent at two to four weeks postnatally, we suggest low-dose systemic glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). In this setting, we suggest low-dose <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> rather than <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In our center, we use a low-dose 10-day regimen. However, the optimal regimen remains uncertain. (See <a class="local">'Dexamethasone'</a> above and <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled and intratracheal glucocorticoid therapy</strong> ‒ Because of the concerns for adverse effects associated with systemic steroids, inhaled glucocorticoids and intratracheal administration (delivered mixed with surfactant) have been proposed as alternatives. (See <a class="local">'Other routes of administration'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest <strong>not</strong> routinely using these therapies for prevention of BPD (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Postnatal inhaled glucocorticoid therapy has not consistently been shown to reduce the risk of BPD, and there are concerns about a possible increased mortality risk. Data on intratracheal glucocorticoid administration are limited and the safety and efficacy of this approach remain uncertain. (See <a class="local">'Inhaled glucocorticoids'</a> above and <a class="local">'Intratracheal glucocorticoids'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Despite the limited data, inhaled glucocorticoid therapy is a reasonable treatment option for older infants with established severe BPD, particularly if they are dependent upon substantial ventilator and oxygen support and have signs of severe airway obstruction or reactive airway disease. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">"Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Glucocorticoids'</a>.)</p><p></p><p class="headingAnchor" id="H1158426119"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James Adams, Jr., MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Htun ZT, Schulz EV, Desai RK, et al. Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. J Perinatol 2021; 41:1783.</a></li><li><a class="nounderline abstract_t">Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. J Perinatol 2009; 29 Suppl 2:S44.</a></li><li><a class="nounderline abstract_t">Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126:800.</a></li><li><a class="nounderline abstract_t">Lemyre B, Dunn M, Thebaud B. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants. Paediatr Child Health 2020; 25:322.</a></li><li><a class="nounderline abstract_t">Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98:289.</a></li><li><a class="nounderline abstract_t">Dassios T, Kaltsogianni O, Hickey A, et al. Chronology and Determinants of Respiratory Function Changes Following Administration of Systemic Postnatal Corticosteroids in Extremely Preterm Infants. J Pediatr 2019; 215:17.</a></li><li><a class="nounderline abstract_t">Buchiboyina AK, Yip CSA, Kohan R, et al. Effect of cumulative dexamethasone dose in preterm infants on neurodevelopmental and growth outcomes: a Western Australia experience. Arch Dis Child Fetal Neonatal Ed 2021; 106:69.</a></li><li><a class="nounderline abstract_t">Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117:75.</a></li><li><a class="nounderline abstract_t">Doyle LW, Cheong JL, Hay S, et al. Early (&amp;lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2021; 10:CD001146.</a></li><li><a class="nounderline abstract_t">Zeng L, Tian J, Song F, et al. Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed 2018; 103:F506.</a></li><li><a class="nounderline abstract_t">Doyle LW, Cheong JL, Hay S, et al. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2021; 11:CD001145.</a></li><li><a class="nounderline abstract_t">Shaffer ML, Baud O, Lacaze-Masmonteil T, et al. Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis. J Pediatr 2019; 207:136.</a></li><li><a class="nounderline abstract_t">Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114:1649.</a></li><li><a class="nounderline abstract_t">Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344:95.</a></li><li><a class="nounderline abstract_t">O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104:15.</a></li><li><a class="nounderline abstract_t">Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115:655.</a></li><li><a class="nounderline abstract_t">Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health 2000; 36:101.</a></li><li><a class="nounderline abstract_t">Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1:1.</a></li><li><a class="nounderline abstract_t">Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98:217.</a></li><li><a class="nounderline abstract_t">Marlow N. Reevaluating Postnatal Steroids for Extremely Preterm Infants to Prevent Lung Disease. JAMA 2017; 317:1317.</a></li><li><a class="nounderline abstract_t">Doyle LW, Halliday HL, Ehrenkranz RA, et al. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 2014; 165:1258.</a></li><li><a class="nounderline abstract_t">Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009; 36:177.</a></li><li><a class="nounderline abstract_t">Kothadia JM, O'Shea TM, Roberts D, et al. Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999; 104:22.</a></li><li><a class="nounderline abstract_t">Kurtom W, Schmidt A, Jain D, et al. Efficacy of late postnatal dexamethasone on weaning from invasive mechanical ventilation in extreme premature infants. J Perinatol 2021; 41:1951.</a></li><li><a class="nounderline abstract_t">Baud O, Maury L, Lebail F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 2016; 387:1827.</a></li><li><a class="nounderline abstract_t">Morris IP, Goel N, Chakraborty M. Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. Eur J Pediatr 2019; 178:1171.</a></li><li><a class="nounderline abstract_t">Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120:40.</a></li><li><a class="nounderline abstract_t">Patra K, Greene MM, Silvestri JM. Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years. J Perinatol 2015; 35:77.</a></li><li><a class="nounderline abstract_t">Peltoniemi OM, Lano A, Yliherva A, et al. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatr 2016; 105:159.</a></li><li><a class="nounderline abstract_t">Baud O, Trousson C, Biran V, et al. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. JAMA 2017; 317:1329.</a></li><li><a class="nounderline abstract_t">Baud O, Trousson C, Biran V, et al. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. Arch Dis Child Fetal Neonatal Ed 2019; 104:F30.</a></li><li><a class="nounderline abstract_t">Alison M, Tilea B, Toumazi A, et al. Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality. Arch Dis Child Fetal Neonatal Ed 2020; 105:520.</a></li><li><a class="nounderline abstract_t">Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116:1.</a></li><li><a class="nounderline abstract_t">Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007; 150:351.</a></li><li><a class="nounderline abstract_t">Needelman H, Hoskoppal A, Roberts H, et al. The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29 weeks' gestation. J Child Neurol 2010; 25:448.</a></li><li><a class="nounderline abstract_t">Kersbergen KJ, de Vries LS, van Kooij BJ, et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr 2013; 163:666.</a></li><li><a class="nounderline abstract_t">Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA 2019; 321:354.</a></li><li><a class="nounderline abstract_t">Watterberg KL, Walsh MC, Li L, et al. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. N Engl J Med 2022; 386:1121.</a></li><li><a class="nounderline abstract_t">Parikh NA, Kennedy KA, Lasky RE, et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013; 162:685.</a></li><li><a class="nounderline abstract_t">Halbmeijer NM, Onland W, Cools F, et al. Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial. JAMA 2021; 326:355.</a></li><li><a class="nounderline abstract_t">Wilson-Costello D, Walsh MC, Langer JC, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009; 123:e430.</a></li><li><a class="nounderline abstract_t">Wood NS, Costeloe K, Gibson AT, et al. The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 2005; 90:F134.</a></li><li><a class="nounderline abstract_t">Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis. JAMA Pediatr 2021; 175:e206826.</a></li><li><a class="nounderline abstract_t">Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006; 118:e1328.</a></li><li><a class="nounderline abstract_t">Cheong JL, Anderson P, Roberts G, et al. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia. Arch Dis Child Fetal Neonatal Ed 2013; 98:F32.</a></li><li><a class="nounderline abstract_t">Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F30.</a></li><li><a class="nounderline abstract_t">Bose CL, Laughon MM. Corticosteroids and chronic lung disease: time for another randomized, controlled trial? Pediatrics 2005; 115:794.</a></li><li><a class="nounderline abstract_t">Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev 2017; 1:CD001969.</a></li><li><a class="nounderline abstract_t">Bassler D, Shinwell ES, Hallman M, et al. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med 2018; 378:148.</a></li><li><a class="nounderline abstract_t">Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 8:CD002311.</a></li><li><a class="nounderline abstract_t">Yeh TF, Chen CM, Wu SY, et al. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2016; 193:86.</a></li><li><a class="nounderline abstract_t">Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008; 121:e1310.</a></li><li><a class="nounderline abstract_t">Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr 2010; 156:537.</a></li><li><a class="nounderline abstract_t">Zhong YY, Li JC, Liu YL, et al. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis. Curr Med Sci 2019; 39:493.</a></li><li><a class="nounderline abstract_t">Venkataraman R, Kamaluddeen M, Hasan SU, et al. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol 2017; 52:968.</a></li><li><a class="nounderline abstract_t">Zheng Y, Xiu W, Lin Y, et al. Long-term effects of the intratracheal administration of corticosteroids for the prevention of bronchopulmonary dysplasia: A meta-analysis. Pediatr Pulmonol 2019; 54:1722.</a></li></ol></div><div id="topicVersionRevision">Topic 5023 Version 65.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34012057" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19399009" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relative adrenal insufficiency in the preterm and term infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20819899" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32765169" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453523" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31500862" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronology and Determinants of Respiratory Function Changes Following Administration of Systemic Postnatal Corticosteroids in Extremely Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32690582" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of cumulative dexamethasone dose in preterm infants on neurodevelopmental and growth outcomes: a Western Australia experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396863" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34674229" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early (&amp;lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29475879" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34758507" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Late (≥7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30416014" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574629" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150359" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390254" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741368" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760004" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11248841" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20389126" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384808" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reevaluating Postnatal Steroids for Extremely Preterm Infants to Prevent Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25217197" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19161874" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Postnatal corticosteroids for bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390255" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34050243" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy of late postnatal dexamethasone on weaning from invasive mechanical ventilation in extreme premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26916176" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31144162" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606560" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26058477" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384828" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321180" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980445" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15995023" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382109" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139411" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29 weeks' gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23706359" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30694322" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35320643" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23140612" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34313697" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204058" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724037" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33720274" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079534" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22684163" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769711" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741388" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Corticosteroids and chronic lung disease: time for another randomized, controlled trial?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052185" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320647" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28836266" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Late (≥7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351971" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18426851" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20138301" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31209823" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28165675" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397120" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term effects of the intratracheal administration of corticosteroids for the prevention of bronchopulmonary dysplasia: A meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
